Clinical trials: Zoster, open to volunteers
Herpes Zoster
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07354659
- Testing
- A zoster mRNA vaccine SYS6017, Active Comparator Vaccine
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Herpes
A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
To evaluate the safety and tolerability of different dosages of recombinant zoster vaccine (CHO cell) when administered to adults aged 40 years and older.
- Trial name
- NCT07633197
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Herpes Zoster
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT06954818
- Testing
- A zoster mRNA vaccine SYS6017
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Systemic Lupus Erythematosus
Safety of the Herpes Zoster Subunit Vaccine in Lupus
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable…
- Trial name
- NCT05559671
- Testing
- Herpes Zoster Subunit (HZ/su) Vaccine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- NYU Langone Health
Varicella Zoster
Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients
This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine.
- Trial name
- NCT06162494
- Testing
- Recombinant Zoster Vaccine
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Herpes Zoster Pain, Neuralgia, Postherpetic
High-Voltage Long-Duration Pulsed Radiofrequency Combined With Liposomal Bupivacaine Subcutaneous Block for Herpes Zoster-Associated Neuralgia
Research Objectives Background and Significance: Zoster-associated neuralgia (ZAN) refers to neuropathic pain experienced by herpes zoster (HZ) patients before, during, and after rash resolution, characterized by paroxysmal…
- Trial name
- NCT06959147
- Testing
- High-Voltage Long-Duration Pulsed Radiofrequency plus Liposomal Bupivacaine group, High-Voltage Long-Duration Pulsed Radiofrequency
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shirong Tan
Varicella (Chickenpox)
SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years
The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines.
- Trial name
- NCT07415252
- Testing
- NBP608 (Mid Potency), NBP608 (Low Potency), Varivax®
- Where
- 14 sites in Honduras, Philippines and 2 more
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life.
- Conditions
- Herpes Zoster, Pain, Postherpetic Neuralgia
- Trial name
- NCT07361796
- Testing
- Venlafaxine combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 832 people
- Sponsor
- Beijing Tiantan Hospital
Herpes Zoster, Mirogabalin
The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia.
- Conditions
- Herpes Zoster, Mirogabalin, Pain
- Trial name
- NCT07307170
- Testing
- Mirogabalin combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Beijing Tiantan Hospital
Herpes Zoster (HZ), Post Herpetic Neuralgia (PHN)
Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia
Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV).
- Trial name
- NCT06969417
- Testing
- Pregabalin, Lacosamide
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- CMH Kharian Medical College
Type 1 Diabetes Mellitus
SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by progressive destruction of pancreatic beta cells mediated by autoreactive T lymphocytes, resulting in absolute insulin deficiency.
- Trial name
- SHIELD-T1D (NCT07614412)
- Testing
- Recombinant Zoster Vaccine (Shingrix; RZV), Semaglutide (Ozempic®)
- Where
- Saudi Arabia
- Volunteers
- 240 people
- Sponsor
- Ministry of Health, Saudi Arabia
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
- Trial name
- NCT06801509
- Testing
- Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Shingrix®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Herpes Zoster
Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine
This is a multicenter retrospective cohort study to evaluate the long-term effectiveness of the live attenuated herpes zoster vaccine within 6 years after vaccination.
- Trial name
- NCT07585370
- Testing
- Attenuated Zoster Vaccine, Live
- Where
- China
- Volunteers
- 24,740 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure
Shingrix in Renal Transplant Recipients
The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant.
- Conditions
- Kidney Transplant Recipient Response to Shingrix Vaccine, Kidney Failure, Kidney Failure, Chronic, Kidney Transplantation
- Trial name
- NCT04128189
- Testing
- Shingrix
- Where
- 4 sites in United States
- Volunteers
- 132 people
- Sponsor
- University of Colorado, Denver
Varicella-zoster Virus
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the vaccine efficacy, safety and immunogenicity of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07817108
- Testing
- ABO1108
- Where
- 4 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Herpes Zoster
Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain
To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute/subacute zoster-associated pain (ZAP) patients.
- Trial name
- NCT06914206
- Testing
- esketamine group, PRF group
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Beijing Tiantan Hospital
Systemic Vasculitis, Spondylarthropathies
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD)…
- Conditions
- Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma
- Trial name
- HZ-REUMA (NCT06763783)
- Testing
- Shingrix, vaccination with 2 doses of Shingrix vaccine
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Region Skane
Oocyte, Zona Pellucida
To Investigate the Relationship Between the Viscoelastic Properties of the Zona Pellucida of Human Oocyte and the Blastocyst Utilization Rate
In in vitro fertilization (IVF) treatment, oocyte quality is one of the key factors influencing the success rate of fertilization.
- Conditions
- Oocyte, Zona Pellucida, Viscoelastic Property
- Trial name
- NCT06839495
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Inti Labs
Vaccine Reaction, Zoster
Reduced Vaccine Response to HZ/su in SLE
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without…
- Conditions
- Vaccine Reaction, Zoster, Systemic Lupus Erythematosus
- Trial name
- NCT07636044
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital